Our world-class neurology research and development organization is pushing towards novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease.

Today there are no treatments to prevent, delay or stop the disease progression.  

Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide.

This disease destroys not only quality of life but also quantity – it is the 3rd leading cause of mortality in people over 65, behind cancer and heart disease.

Alzheimer’s disease is usually diagnosed in people 65 and older, but it starts earlier with subtle neurological changes occurring years or even decades before symptoms appear.  Many people are experiencing the early, often unrecognized, signs of mild cognitive impairment.

Driven by our commitment to patients and our strong business foundation, Biogen remains commited to furthering Alzheimer’s disease research and treatment, aiming to help address the unmet needs in this devastating condition, with an emphasis on early-stage disease.